PREMARIN (conjugated estrogens tablets, USP) for oral administration contains a mixture of conjugated estrogens purified from pregnant mares' urine and consists of the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains concomitant components as sodium sulfate conjugates, 17α-dihydroequilin, 17α estradiol, and 17β-dihydroequilin. Tablets for oral administration are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of conjugated estrogens.
PREMARIN 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, carnauba wax, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, powdered cellulose, sucrose, and titanium dioxide. Each tablet strength contains the following colors:
| Tablet strength | Tablet color contains |
|---|---|
0.3 mg | D&C Yellow No. 10 and FD&C Blue No. 2 |
0.45 mg | FD&C Blue No. 2 |
0.625 mg | FD&C Blue No. 2 and FD&C Red No. 40 |
0.9 mg | D&C Red No. 30 and D&C Red No. 7 |
1.25 mg | Black iron oxide, D&C Yellow No. 10 and FD&C Yellow No. 6 |
PREMARIN tablets comply with USP Dissolution Test criteria, as outlined below:
PREMARIN 1.25 mg tablets | USP Dissolution Test 4 |
PREMARIN 0.3 mg, 0.45 mg and 0.625 mg tablets | USP Dissolution Test 5 |
PREMARIN 0.9 mg tablets | USP Dissolution Test 6 |
PREMARIN (conjugated estrogens tablets, USP) for oral administration contains a mixture of conjugated estrogens purified from pregnant mares' urine and consists of the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains concomitant components as sodium sulfate conjugates, 17α-dihydroequilin, 17α estradiol, and 17β-dihydroequilin. Tablets for oral administration are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths of conjugated estrogens.
PREMARIN 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets also contain the following inactive ingredients: calcium phosphate tribasic, carnauba wax, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, powdered cellulose, sucrose, and titanium dioxide. Each tablet strength contains the following colors:
| Tablet strength | Tablet color contains |
|---|---|
0.3 mg | D&C Yellow No. 10 and FD&C Blue No. 2 |
0.45 mg | FD&C Blue No. 2 |
0.625 mg | FD&C Blue No. 2 and FD&C Red No. 40 |
0.9 mg | D&C Red No. 30 and D&C Red No. 7 |
1.25 mg | Black iron oxide, D&C Yellow No. 10 and FD&C Yellow No. 6 |
PREMARIN tablets comply with USP Dissolution Test criteria, as outlined below:
PREMARIN 1.25 mg tablets | USP Dissolution Test 4 |
PREMARIN 0.3 mg, 0.45 mg and 0.625 mg tablets | USP Dissolution Test 5 |
PREMARIN 0.9 mg tablets | USP Dissolution Test 6 |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.